breastcancerwomenage 55-64 y.o.raloxifenePREVENTequationcardiovasculardisease75y.o.ovariancancerHIV40-59 y.o.,ASCVD ≥10%, lowbleeding riskinsufficientevidenceforscreeningHepatitisBdementiapneumococcalaromataseinhibitorsTimedup andgo testFractureRiskAssessmentTool40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorhypertensiontamoxifendepressionTyrer-Cuzickmodelaspirin1 dose; 2doses (2-6monthsapart) ifimmunocomp60y.o.Gailmodelq1-2ymammogrambased on lifeexpectancy /health statusHepatitisC≥6.5%lungcancercommunity-dwelling,postmenopausalwomenanxietyq15yq5ydiabetes≥ 100mg/dLcervicalcancer2 doses,2-6monthsapart40y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq1ymammogram≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors65y.o.q3ytobaccouse40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor50y.o.herpeszoster≥ 200mg/dL3%q2y≥20%≥5.7%q1y≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≤q2y< 60y.o.overweight/ obesitydyslipidemia52y.o.colorectalcancerhormonetherapystatinmultidoseinitial series,then 1 doseat 2-6months≥ 126mg/dLbreastcancerwomenage 55-64 y.o.raloxifenePREVENTequationcardiovasculardisease75y.o.ovariancancerHIV40-59 y.o.,ASCVD ≥10%, lowbleeding riskinsufficientevidenceforscreeningHepatitisBdementiapneumococcalaromataseinhibitorsTimedup andgo testFractureRiskAssessmentTool40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorhypertensiontamoxifendepressionTyrer-Cuzickmodelaspirin1 dose; 2doses (2-6monthsapart) ifimmunocomp60y.o.Gailmodelq1-2ymammogrambased on lifeexpectancy /health statusHepatitisC≥6.5%lungcancercommunity-dwelling,postmenopausalwomenanxietyq15yq5ydiabetes≥ 100mg/dLcervicalcancer2 doses,2-6monthsapart40y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq1ymammogram≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors65y.o.q3ytobaccouse40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor50y.o.herpeszoster≥ 200mg/dL3%q2y≥20%≥5.7%q1y≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≤q2y< 60y.o.overweight/ obesitydyslipidemia52y.o.colorectalcancerhormonetherapystatinmultidoseinitial series,then 1 doseat 2-6months≥ 126mg/dL

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. breast cancer
  2. women age 55-64 y.o.
  3. raloxifene
  4. PREVENT equation
  5. cardiovascular disease
  6. 75 y.o.
  7. ovarian cancer
  8. HIV
  9. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  10. insufficient evidence for screening
  11. Hepatitis B
  12. dementia
  13. pneumococcal
  14. aromatase inhibitors
  15. Timed up and go test
  16. Fracture Risk Assessment Tool
  17. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  18. hypertension
  19. tamoxifen
  20. depression
  21. Tyrer-Cuzick model
  22. aspirin
  23. 1 dose; 2 doses (2-6 months apart) if immunocomp
  24. 60 y.o.
  25. Gail model
  26. q1-2y mammogram based on life expectancy / health status
  27. Hepatitis C
  28. ≥ 6.5%
  29. lung cancer
  30. community-dwelling, postmenopausal women
  31. anxiety
  32. q15y
  33. q5y
  34. diabetes
  35. ≥ 100 mg/dL
  36. cervical cancer
  37. 2 doses, 2-6 months apart
  38. 40 y.o.
  39. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  40. q1y mammogram
  41. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  42. 65 y.o.
  43. q3y
  44. tobacco use
  45. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  46. 50 y.o.
  47. herpes zoster
  48. ≥ 200 mg/dL
  49. 3%
  50. q2y
  51. ≥ 20%
  52. ≥ 5.7%
  53. q1y
  54. ≥ 140 mg/dL
  55. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  56. ≤ q2y
  57. < 60 y.o.
  58. overweight / obesity
  59. dyslipidemia
  60. 52 y.o.
  61. colorectal cancer
  62. hormone therapy
  63. statin
  64. multidose initial series, then 1 dose at 2-6 months
  65. ≥ 126 mg/dL